iCAD (ICAD) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 10, 2023
Document Information [Line Items]
Entity Central Index Key	0000749660
Entity Registrant Name	iCAD INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	02-0377419
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, City or Town	Nashua
Entity Address, State or Province	NH
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ICAD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		25,446,407

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,663	$ 21,313
Trade accounts receivable, net of allowance for credit losses of $922 as of both March 31, 2023 and December 31, 2022	7,381	8,898
Inventory, net	4,866	5,389
Prepaid expenses and other current assets	2,292	2,641
Total current assets	34,202	38,241
Property and equipment, net of accumulated depreciation of $2,151 and $2,135 as of March 31, 2023 and December 31, 2022, respectively	1,153	1,074
Operating lease assets	3,200	3,361
Other assets	55	69
Intangible assets, net of accumulated amortization of $8,980 and $8,932 as of March 31, 2023 and December 31, 2022, respectively	436	482
Goodwill	8,362	8,362
Deferred tax assets	111	116
Total assets	47,519	51,705
Current liabilities:
Accounts payable	1,888	1,973
Accrued and other expenses	4,213	4,681
Less: current portion of lease liabilities	569	582
Deferred revenue—current portion	6,211	6,216
Total current liabilities	12,881	13,452
Long-term lease liabilities	2,639	2,803
Deferred revenue, net of current	283	542
Deferred tax	6	6
Total liabilities	15,809	16,803
Commitments and Contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued.	0	0
Outstanding 25,260,576 as of both March 31, 2023 and December 31, 2022.	254	254
Additional paid-in capital	303,485	302,899
Accumulated deficit	(270,614)	(266,836)
Treasury stock at cost, 185,831 shares as of both March 31, 2023 and December 31, 2022	(1,415)	(1,415)
Total stockholders’ equity	31,710	34,902
Total liabilities and stockholders’ equity	$ 47,519	$ 51,705

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Allowance for doubtful accounts on trade accounts receivable	$ 922	$ 922
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	2,151	2,135
Intangible assets, accumulated amortization	$ 8,980	$ 8,932
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	25,446,407	25,446,407
Common stock, shares outstanding (in shares)	25,260,576	25,260,576
Treasury Stock, Common, Shares (in shares)	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Revenue	$ 5,778,000	$ 7,523,000
Cost of revenue:
Cost of revenue	1,648,000	2,211,000
Gross profit	4,130,000	5,312,000
Operating expenses:
Engineering and product development	2,281,000	2,275,000
Marketing and sales	2,857,000	3,565,000
General and administrative	2,862,000	2,931,000
Amortization and depreciation	55,000	63,000
Total operating expenses	8,055,000	8,834,000
Loss from operations	(3,925,000)	(3,522,000)
Other income/ (expense):
Interest expense	0	(9,000)
Interest income	150,000	0
Other income (expense), net	2,000	(13,000)
Other income (expense), net	152,000	(22,000)
Loss before provision for income taxes	(3,773,000)	(3,544,000)
Provision for tax expense	(5,000)	(1,000)
Net loss and comprehensive loss	$ (3,778,000)	$ (3,545,000)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.15)	$ (0.14)
Weighted average number of shares used in computing loss per share:
Basic and diluted (in shares)	25,261	25,160
Product [Member]
Revenue:
Revenue	$ 2,744,000	$ 4,560,000
Cost of revenue:
Cost of revenue	586,000	1,087,000
Service and Supplies [Member]
Revenue:
Revenue	3,034,000	2,963,000
Cost of revenue:
Cost of revenue	993,000	1,049,000
Amortization and Depreciation [Member]
Cost of revenue:
Cost of revenue	$ 69,000	$ 75,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Dec. 31, 2021	25,326,086
Balance at Dec. 31, 2021	$ 253	$ 300,859	$ (253,180)	$ (1,415)	$ 46,517
Stock-based compensation	0	655	0	0	655
Net loss	$ 0	0	(3,545)	0	(3,545)
Issuance of common stock relative to vesting of restricted stock (in shares)	875
Issuance of common stock relative to vesting of restricted stock	$ 1	0	0	0	$ 0
Issuance of common stock pursuant to stock option plans (in shares)	22,833				22,833
Issuance of common stock pursuant to stock option plans	$ 1	66	0	0	$ 66
Issuance of common stock pursuant Employee Stock Purchase Plans (in shares)	9,381
Issuance of common stock pursuant Employee Stock Purchase Plans	$ 0	60	0	0	60
Balance (in shares) at Mar. 31, 2022	25,359,175
Balance at Mar. 31, 2022	$ 253	301,640	(256,725)	(1,415)	43,753
Balance (in shares) at Dec. 31, 2022	25,446,407
Balance at Dec. 31, 2022	$ 254	302,899	(266,836)	(1,415)	34,902
Stock-based compensation	0	586	0	0	586
Net loss	$ 0	0	(3,778)	0	$ (3,778)
Issuance of common stock pursuant to stock option plans (in shares)					0
Balance (in shares) at Mar. 31, 2023	25,446,407
Balance at Mar. 31, 2023	$ 254	$ 303,485	$ (270,614)	$ (1,415)	$ 31,710

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities:
Net loss	$ (3,778,000)	$ (3,545,000)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	46,000	53,000
Depreciation	78,000	86,000
Non-cash lease expense	161,000	200,000
Bad debt provision	0	305,000
Stock-based compensation	586,000	655,000
Deferred tax	5,000	1,000
Changes in operating assets and liabilities:
Accounts receivable	1,517,000	(1,723,000)
Inventory	523,000	(565,000)
Prepaid and other assets	363,000	653,000
Accounts payable	(120,000)	(84,000)
Accrued and other expenses	(468,000)	(514,000)
Lease liabilities	(177,000)	(214,000)
Deferred revenue	(264,000)	243,000
Total adjustments	2,250,000	(904,000)
Net cash used for operating activities	(1,528,000)	(4,449,000)
Cash flow from investing activities:
Additions to patents, technology and other	0	(10,000)
Additions to property and equipment	(122,000)	(151,000)
Net cash used for investing activities	(122,000)	(161,000)
Cash flow from financing activities:
Proceeds from option exercises pursuant to stock option plans	0	66,000
Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plans	0	60,000
Net cash provided by financing activities	0	126,000
(Decrease) increase in cash and cash equivalents	(1,650,000)	(4,484,000)
Cash and cash equivalents, beginning of period	21,313,000	34,282,000
Cash and cash equivalents, end of period	19,663,000	29,798,000
Supplemental disclosure of cash flow information:
Interest paid	$ 0	$ 9,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may March 31, 2023 three March 31, 2023 2022 three March 31, 2023 2022 three March 31, 2023 2022 Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not 10 December 31, 2022 March 31, 2023. three March 31, 2023 not may December 31, 2023, Principles of Consolidation and Business Segments The condensed consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, iCAD France, LLC and iCAD Italy, LLC. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products for the detection of cancer. The Therapy segment consists of radiation therapy (“Xoft”, “Axxent”) products for the treatment of certain cancers. Risk and Uncertainty On March 12, 2020, 19 19, March 31, 2023, 19 In late February 2022, March 31, 2023 may may may not three March 31, 2023, Recently Adopted Accounting Pronouncements In June 2016, 2016 13, 326 2016 13 2016 13 November 2019, 2016 13 December 15, 2022. 2016 13 2016 13 January 1, 2023. twelve 2016 13 not Recently Issued Accounting Standards ( Not There are no not March 31, 2023

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 2 Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, 820” three first two • Level 1 • Level 2 1 not • Level 3 no The assigned level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Money market funds included in cash and cash equivalents in the accompanying consolidated balance sheet are considered a Level 1 The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of March 31, 2023 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 14,949 $ — $ — $ 14,949 Total Assets $ 14,949 $ — $ — $ 14,949 Fair Value Measurements as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,067 $ — $ — $ 15,067 Total Assets $ 15,067 $ — $ — $ 15,067 There were no Level 2 3 March 31, 2023 December 31, 2022

Note 3 - Revenue

Note 3 - Revenue	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 3 Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments. Three months ended March 31, 2023 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,460 $ 284 $ 2,744 Service contracts 1,874 372 2,246 Supply and source usage agreements — 493 493 Disposable applicators — 225 225 Other — 70 70 $ 4,334 $ 1,444 $ 5,778 Timing of Revenue Recognition Goods transferred at a point in time $ 2,028 $ 608 $ 2,636 Services transferred over time 2,306 836 3,142 $ 4,334 $ 1,444 $ 5,778 Sales Channels Direct sales force $ 2,778 $ 1,056 $ 3,834 OEM partners 1,556 — 1,556 Channel partners — 388 388 $ 4,334 $ 1,444 $ 5,778 Three months ended March 31, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,864 $ 696 $ 4,560 Service contracts 1,657 386 2,043 Supply and source usage agreements — 413 413 Disposable applicators — 415 415 Other — 92 92 $ 5,521 $ 2,002 $ 7,523 Timing of Revenue Recognition Goods transferred at a point in time $ 3,881 $ 1,264 $ 5,145 Services transferred over time 1,640 738 2,378 $ 5,521 $ 2,002 $ 7,523 Sales Channels Direct sales force $ 2,895 $ 815 $ 3,710 OEM partners 2,626 — 2,626 Channel partners — 1,187 1,187 $ 5,521 $ 2,002 $ 7,523 Products. Service Sources and Source Usage Agreements Disposable applicators Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current contract assets are a component of other assets. The following table provides information about receivables, current and non-current contract assets, and contract liabilities from contracts with customers. Contract balances Balance at Balance at March 31, 2023 December 31, 2022 Receivables, which are included in ‘Trade accounts receivable’ $ 7,381 $ 8,898 Current contract assets, which are included in “Prepaid and other assets” $ 638 $ 759 Non-current contract assets, which are included in “other assets” $ — $ 15 Contract liabilities, which are included in “Deferred revenue” $ 6,494 $ 6,758 Timing of revenue recognition may The Company records net contract assets or contract liabilities on a contract-by-contract basis. The Company records a contract asset for unbilled revenue when the Company’s performance is in excess of amounts billed or billable. The Company classifies the net contract asset as either a current or non-current based on the expected timing of the Company’s right to bill under the terms of the contract. The current contract asset balance primarily relates to the net unbilled revenue balances with two one one one Changes in deferred revenue from contracts with customers were as follows: Three Months Ended March 31, 2023 Balance at beginning of period $ 6,758 Deferral of revenue 5,514 Recognition of deferred revenue (5,778 ) Balance at end of period $ 6,494 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $3.4 million in 2023, 2024, 2025 2026.

Note 4 - Net Loss Per Common Sh

Note 4 - Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 4 Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in 000s, Three Months Ended March 31, 2023 2022 Net loss $ (3,778 ) $ (3,545 ) Shares used in the calculation of basic and diluted net loss per share 25,261 25,160 Net loss per share - basic and diluted $ (0.15 ) $ (0.14 ) The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: March 31, 2023 2022 Stock options 2,946,470 2,894,449 Total 2,946,470 2,894,449

Note 5 - Inventories

Note 5 - Inventories	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 5 Inventories The Company values its inventory at the lower of cost or net realizable value. Cost includes materials, labor, and manufacturing overhead and is determined using the first first March 31, 2023 December 31, 2022. March 31, 2023 December 31, 2022 Raw materials $ 3,113 $ 2,658 Work in process 213 101 Finished Goods 1,802 2,892 Inventory Gross 5,128 5,651 Inventory Reserve (262 ) (262 ) Inventory Net $ 4,866 $ 5,389

Note 6 - Goodwill

Note 6 - Goodwill	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Goodwill Disclosure [Text Block]	Note 6 Goodwill The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company considered indicators of impairment, and there were no no three March 31, 2023 2022.

Note 7 - Long-lived Assets

Note 7 - Long-lived Assets	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 7 Long-lived Assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not There is no may not • A significant decrease in the market price of a long-lived asset (or asset group); • A significant adverse change in the extent or manner in which a long-lived asset (or asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (or asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (or asset group); and • A current operating period, or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (or asset group). The Company determined there were no March 31, 2023

Note 8 - Lease Commitments

Note 8 - Lease Commitments	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 8 Lease Commitments In accordance with ASC Topic 842, 842" At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company calculates an incremental borrowing rate, which is determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an extension option if the Company is reasonably certain to exercise that option. Assumptions made by the Company at the commencement date of each lease are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not Right-of-use assets and obligations for leases with an initial term of 12 not not third not 606 ASC 842 three March 31, 2023 Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease components that transfer a distinct service to the Company, such as common area maintenance services. The Company has elected to separate the accounting for lease components and non-lease components for real estate and equipment leases. Components of Leases: The Company has leases for office space and office equipment. The leases expire at various dates through 2028. Three Months Ended Lease Cost Classification March 31, 2023 Operating lease cost - Right of Use Asset Operating expenses $ 216 Other information related to leases was as follows: Three Months Ended March 31, 2023 Cash paid from operating cash flows for operating leases $ 232 As of March 31, 2023 Weighted-average remaining lease term of operating leases (years) 3.6 Weighted-average discount rate for operating leases 7.0 % Maturity of the Company’s lease liabilities as of March 31, 2023 2023 $ 549 2024 846 2025 848 2026 749 2027 685 2028 172 Total lease payments 3,849 Less: effects of discounting (641 ) Total lease liabilities 3,208 Less: current portion of lease liabilities 569 Long-term lease liabilities $ 2,639

Note 9 - Stockholders Equity

Note 9 - Stockholders Equity	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 9 Stockholders Equity Stock-Based Compensation The Company granted options to purchase 541,142 shares of the Company’s stock during the three March 31, 2023 first three 2023 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows: Three Months Ended March 31, 2023 2022 Cost of revenue $ 1 $ — Engineering and product development 73 68 Marketing and sales 131 199 General and administrative 381 388 $ 586 $ 655 During the three March 31, 2023, five four 2023. one 60 As of March 31, 2023 Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended March 31, 2023 2022 Average risk-free interest rate 4.19 % 1.46 % Expected dividend yield None None Expected life (in years) 3.0 3.5 Expected volatility 72.69% - 77.53% 66.3% - 69.5% Weighted average exercise price $ 2.16 $ 5.22 Weighted average fair value $ 1.14 $ 2.56 The Company’s 2023 2022 zero not The Company did not three March 31, 2023 2022 one first one A summary of stock option activity for all stock option plans for the period ended March 31, 2023 Number of Weighted Average Intrinsic Options Exercise Price Value Outstanding as of December 31, 2022 2,610,992 $ 7.54 $ — Granted 541,142 $ 2.16 $ — Exercised — $ — $ — Cancelled (204,331 ) $ 9.27 $ — Outstanding as of March 31, 2023 2,947,803 $ 9.44 $ — Options Exercisable as of December 31, 2022 1,619,855 $ 6.47 $ — Options Exercisable as of March 31, 2023 1,985,026 $ 7.44 $ — The Company issued 0 and 22,833 shares of common stock upon the exercise of outstanding stock options in the three March 31, 2023 2022, three March 31, 2022. Employee Stock Purchase Plan In December 2019, 2019 January 1, 2020. may October 2022, October 1, 2022 December 31, 2022 not Substantially all of the Company’s employees whose customary employment is for more than 20 not Prior to the Company's suspension of the Plan, any eligible employee could enroll as of the beginning of a respective quarterly accumulation period. Employees who participated in the ESPP were able to purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdrew from participation, accumulated payroll deductions were used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first no The Company issued 9,381 shares under the ESPP in the three March 31, 2022. three March 31, 2022.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10 Income Taxes The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which the Company operates and the development of tax planning strategies during the year. As such, there can be significant volatility in interim tax provisions. Income tax expense was approximately $5,000 and $1,000 for the three March 31, 2023 2022 , three March 31, 2023 2022 2023 2022

Note 11 - Segment Reporting

Note 11 - Segment Reporting	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 11 Segment Reporting Operating segments are the components of the Company’s business for which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is the chief executive officer. The Company’s operating segments are generally organized by the type of product or service offered and by geography. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments: Detection and Therapy. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no The Company does not not Three Months Ended March 31, 2023 2022 Segment revenues: Detection $ 4,334 $ 5,521 Therapy 1,444 2,002 Total revenue $ 5,778 $ 7,523 Segment gross profit: Detection $ 3,544 $ 4,661 Therapy 586 651 Segment gross profit $ 4,130 $ 5,312 Segment operating income (loss): Detection $ (124 ) $ 622 Therapy (883 ) (1,209 ) Segment operating income (loss): $ (1,007 ) $ (587 ) General, administrative, depreciation and amortization expense $ (2,918 ) $ (2,935 ) Interest expense — (9 ) Interest income 150 — Other expense 2 (13 ) Loss before income tax $ (3,773 ) $ (3,544 )

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 12 Commitments and Contingencies Other Commitments The Company is obligated to pay approximately $4.2 million for firm purchase obligations to suppliers for future product and service deliverables and $0.2 million for minimum royalty obligations. Litigation The Company may no not 450,

Note 13 - Restructuring

Note 13 - Restructuring	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 13 Restructuring On March 20, 2023, During the three March 31, 2023, 2023 no one may 2023. The Company's accrual for restructuring charges for the three March 31, 2023 Balance of as January 31, 2023 $ — Charges 76 Cash payments — Balance as of March 31, 2023 $ 76

Note 14 - Subsequent Events

Note 14 - Subsequent Events	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 14 Subsequent Events The Company has evaluated events and transactions subsequent to the balance sheet date to the date of the filing and is not

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may March 31, 2023 three March 31, 2023 2022 three March 31, 2023 2022 three March 31, 2023 2022 Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not 10 December 31, 2022 March 31, 2023. three March 31, 2023 not may December 31, 2023,
Principles of Consolidation and Business Segments [Policy Text Block]	Principles of Consolidation and Business Segments The condensed consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, iCAD France, LLC and iCAD Italy, LLC. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products for the detection of cancer. The Therapy segment consists of radiation therapy (“Xoft”, “Axxent”) products for the treatment of certain cancers.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Risk and Uncertainty On March 12, 2020, 19 19, March 31, 2023, 19 In late February 2022, March 31, 2023 may may may not three March 31, 2023,
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In June 2016, 2016 13, 326 2016 13 2016 13 November 2019, 2016 13 December 15, 2022. 2016 13 2016 13 January 1, 2023. twelve 2016 13 not Recently Issued Accounting Standards ( Not There are no not March 31, 2023

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Assets Money market accounts $ 14,949 $ — $ — $ 14,949 Total Assets $ 14,949 $ — $ — $ 14,949 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,067 $ — $ — $ 15,067 Total Assets $ 15,067 $ — $ — $ 15,067

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended March 31, 2023 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,460 $ 284 $ 2,744 Service contracts 1,874 372 2,246 Supply and source usage agreements — 493 493 Disposable applicators — 225 225 Other — 70 70 $ 4,334 $ 1,444 $ 5,778 Timing of Revenue Recognition Goods transferred at a point in time $ 2,028 $ 608 $ 2,636 Services transferred over time 2,306 836 3,142 $ 4,334 $ 1,444 $ 5,778 Sales Channels Direct sales force $ 2,778 $ 1,056 $ 3,834 OEM partners 1,556 — 1,556 Channel partners — 388 388 $ 4,334 $ 1,444 $ 5,778 Three months ended March 31, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,864 $ 696 $ 4,560 Service contracts 1,657 386 2,043 Supply and source usage agreements — 413 413 Disposable applicators — 415 415 Other — 92 92 $ 5,521 $ 2,002 $ 7,523 Timing of Revenue Recognition Goods transferred at a point in time $ 3,881 $ 1,264 $ 5,145 Services transferred over time 1,640 738 2,378 $ 5,521 $ 2,002 $ 7,523 Sales Channels Direct sales force $ 2,895 $ 815 $ 3,710 OEM partners 2,626 — 2,626 Channel partners — 1,187 1,187 $ 5,521 $ 2,002 $ 7,523
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Balance at March 31, 2023 December 31, 2022 Receivables, which are included in ‘Trade accounts receivable’ $ 7,381 $ 8,898 Current contract assets, which are included in “Prepaid and other assets” $ 638 $ 759 Non-current contract assets, which are included in “other assets” $ — $ 15 Contract liabilities, which are included in “Deferred revenue” $ 6,494 $ 6,758
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Three Months Ended March 31, 2023 Balance at beginning of period $ 6,758 Deferral of revenue 5,514 Recognition of deferred revenue (5,778 ) Balance at end of period $ 6,494

Note 4 - Net Loss Per Common _2

Note 4 - Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2023 2022 Net loss $ (3,778 ) $ (3,545 ) Shares used in the calculation of basic and diluted net loss per share 25,261 25,160 Net loss per share - basic and diluted $ (0.15 ) $ (0.14 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2023 2022 Stock options 2,946,470 2,894,449 Total 2,946,470 2,894,449

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2023 December 31, 2022 Raw materials $ 3,113 $ 2,658 Work in process 213 101 Finished Goods 1,802 2,892 Inventory Gross 5,128 5,651 Inventory Reserve (262 ) (262 ) Inventory Net $ 4,866 $ 5,389

Note 8 - Lease Commitments (Tab

Note 8 - Lease Commitments (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Lease Cost Classification March 31, 2023 Operating lease cost - Right of Use Asset Operating expenses $ 216 Three Months Ended March 31, 2023 Cash paid from operating cash flows for operating leases $ 232 As of March 31, 2023 Weighted-average remaining lease term of operating leases (years) 3.6 Weighted-average discount rate for operating leases 7.0 %
Financing Lease and Lessee Operating Lease Liability Maturity [Table Text Block]	2023 $ 549 2024 846 2025 848 2026 749 2027 685 2028 172 Total lease payments 3,849 Less: effects of discounting (641 ) Total lease liabilities 3,208 Less: current portion of lease liabilities 569 Long-term lease liabilities $ 2,639

Note 9 - Stockholders Equity (T

Note 9 - Stockholders Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2023 2022 Cost of revenue $ 1 $ — Engineering and product development 73 68 Marketing and sales 131 199 General and administrative 381 388 $ 586 $ 655
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2023 2022 Average risk-free interest rate 4.19 % 1.46 % Expected dividend yield None None Expected life (in years) 3.0 3.5 Expected volatility 72.69% - 77.53% 66.3% - 69.5% Weighted average exercise price $ 2.16 $ 5.22 Weighted average fair value $ 1.14 $ 2.56
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Average Intrinsic Options Exercise Price Value Outstanding as of December 31, 2022 2,610,992 $ 7.54 $ — Granted 541,142 $ 2.16 $ — Exercised — $ — $ — Cancelled (204,331 ) $ 9.27 $ — Outstanding as of March 31, 2023 2,947,803 $ 9.44 $ — Options Exercisable as of December 31, 2022 1,619,855 $ 6.47 $ — Options Exercisable as of March 31, 2023 1,985,026 $ 7.44 $ —

Note 11 - Segment Reporting (Ta

Note 11 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended March 31, 2023 2022 Segment revenues: Detection $ 4,334 $ 5,521 Therapy 1,444 2,002 Total revenue $ 5,778 $ 7,523 Segment gross profit: Detection $ 3,544 $ 4,661 Therapy 586 651 Segment gross profit $ 4,130 $ 5,312 Segment operating income (loss): Detection $ (124 ) $ 622 Therapy (883 ) (1,209 ) Segment operating income (loss): $ (1,007 ) $ (587 ) General, administrative, depreciation and amortization expense $ (2,918 ) $ (2,935 ) Interest expense — (9 ) Interest income 150 — Other expense 2 (13 ) Loss before income tax $ (3,773 ) $ (3,544 )

Note 13 - Restructuring (Tables

Note 13 - Restructuring (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Restructuring and Related Costs [Table Text Block]	Balance of as January 31, 2023 $ — Charges 76 Cash payments — Balance as of March 31, 2023 $ 76

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Significant Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2023
Number of Operating Segments	2
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]
Concentration Risk, Percentage	15%

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure, Total	$ 0	$ 0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure, Total	$ 0	$ 0

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	$ 0	$ 0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member]
Assets, fair value	14,949	15,067
Fair Value, Recurring [Member] | Money Market Funds [Member]
Assets, fair value	14,949	15,067
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	14,949	15,067
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets, fair value	14,949	15,067
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Assets, fair value	$ 0	$ 0

Note 3 - Revenue 1 (Details Tex

Note 3 - Revenue 1 (Details Textual)	3 Months Ended
	Mar. 31, 2023
Minimum [Member]
Service Contracts, Term (Year)	12 years
Maximum [Member]
Service Contracts, Term (Year)	48 years

Note 3 - Revenue 2 (Details Tex

Note 3 - Revenue 2 (Details Textual) $ in Millions	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Amount	$ 3.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 0.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year

Note 3 - Revenue - Revenues Dis

Note 3 - Revenue - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from contracts with customers	$ 5,778	$ 7,523
Direct Sales Force [Member]
Revenue from contracts with customers	3,834	3,710
OEM Partners [Member]
Revenue from contracts with customers	1,556	2,626
Channel Partners [Member]
Revenue from contracts with customers	388	1,187
Transferred at Point in Time [Member]
Revenue from contracts with customers	2,636	5,145
Transferred over Time [Member]
Revenue from contracts with customers	3,142	2,378
Product [Member]
Revenue from contracts with customers	2,744	4,560
Service Contracts [Member]
Revenue from contracts with customers	2,246	2,043
Supply and Source Usage Agreements [Member]
Revenue from contracts with customers	493	413
Disposable Applicators [Member]
Revenue from contracts with customers	225	415
Other [Member]
Revenue from contracts with customers	70	92
Detection [Member]
Revenue from contracts with customers	4,334	5,521
Detection [Member] | Direct Sales Force [Member]
Revenue from contracts with customers	2,778	2,895
Detection [Member] | OEM Partners [Member]
Revenue from contracts with customers	1,556	2,626
Detection [Member] | Channel Partners [Member]
Revenue from contracts with customers	0	0
Detection [Member] | Transferred at Point in Time [Member]
Revenue from contracts with customers	2,028	3,881
Detection [Member] | Transferred over Time [Member]
Revenue from contracts with customers	2,306	1,640
Detection [Member] | Product [Member]
Revenue from contracts with customers	2,460	3,864
Detection [Member] | Service Contracts [Member]
Revenue from contracts with customers	1,874	1,657
Detection [Member] | Supply and Source Usage Agreements [Member]
Revenue from contracts with customers	0	0
Detection [Member] | Disposable Applicators [Member]
Revenue from contracts with customers	0	0
Detection [Member] | Other [Member]
Revenue from contracts with customers	0	0
Therapy [Member]
Revenue from contracts with customers	1,444	2,002
Therapy [Member] | Direct Sales Force [Member]
Revenue from contracts with customers	1,056	815
Therapy [Member] | OEM Partners [Member]
Revenue from contracts with customers	0	0
Therapy [Member] | Channel Partners [Member]
Revenue from contracts with customers	388	1,187
Therapy [Member] | Transferred at Point in Time [Member]
Revenue from contracts with customers	608	1,264
Therapy [Member] | Transferred over Time [Member]
Revenue from contracts with customers	836	738
Therapy [Member] | Product [Member]
Revenue from contracts with customers	284	696
Therapy [Member] | Service Contracts [Member]
Revenue from contracts with customers	372	386
Therapy [Member] | Supply and Source Usage Agreements [Member]
Revenue from contracts with customers	493	413
Therapy [Member] | Disposable Applicators [Member]
Revenue from contracts with customers	225	415
Therapy [Member] | Other [Member]
Revenue from contracts with customers	$ 70	$ 92

Note 3 - Revenue - Summary of R

Note 3 - Revenue - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Receivables, which are included in ‘Trade accounts receivable’	$ 7,381	$ 8,898
Current contract assets, which are included in “Prepaid and other assets”	638	759
Non-current contract assets, which are included in “other assets”	0	15
Contract liabilities, which are included in “Deferred revenue”	$ 6,494	$ 6,758

Note 3 - Revenue - Summary of C

Note 3 - Revenue - Summary of Changes in Deferred Revenue from Contracts with Customers (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Balance at beginning of period	$ 6,758
Deferral of revenue	5,514
Recognition of deferred revenue	(5,778)
Balance at end of period	$ 6,494

Note 4 - Net Loss Per Common _3

Note 4 - Net Loss Per Common Share - Calculation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net loss	$ (3,778)	$ (3,545)
Shares used in the calculation of basic and diluted net loss per share (in shares)	25,261	25,160
Basic and diluted (in dollars per share)	$ (0.15)	$ (0.14)

Note 4 - Net Loss Per Common _4

Note 4 - Net Loss Per Common Share - Schedule of Anti-dilutive Shares Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive securities (in shares)	2,946,470	2,894,449
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	2,946,470	2,894,449

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Valuation Reserves	$ 262	$ 262

Note 5 - Inventory - Schedule o

Note 5 - Inventory - Schedule of Current Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Raw materials	$ 3,113	$ 2,658
Work in process	213	101
Finished Goods	1,802	2,892
Inventory Gross	5,128	5,651
Inventory Reserve	(262)	(262)
Inventory Net	$ 4,866	$ 5,389

Note 6 - Goodwill (Details Text

Note 6 - Goodwill (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Goodwill, Impairment Loss	$ 0	$ 0

Note 8 - Lease Commitments (Det

Note 8 - Lease Commitments (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Operating Lease, Impairment Loss	$ 0

Note 8 - Lease Commitments - Sc

Note 8 - Lease Commitments - Schedule of Components of Lease Expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Operating lease cost - Right of Use Asset	$ 216
Cash paid from operating cash flows for operating leases	$ 232
Weighted-average remaining lease term of operating leases (years) (Year)	3 years 7 months 6 days
Weighted-average discount rate for operating leases	7%

Note 8 - Lease Commitments - Su

Note 8 - Lease Commitments - Summary of Detained Information of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
2023	$ 549
2024	846
2025	848
2026	749
2027	685
2028	172
Total lease payments	3,849
Less: effects of discounting	(641)
Total lease liabilities	3,208
Less: current portion of lease liabilities	569	$ 582
Long-term lease liabilities	$ 2,639	$ 2,803

Note 9 - Stockholders Equity (D

Note 9 - Stockholders Equity (Details Textual)	3 Months Ended
	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares	541,142
Share-Based Payment Arrangement, Expense	$ 586,000	$ 655,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 1,600,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 1 month 2 days
Dividends, Common Stock	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | shares	0	22,833
Proceeds from Stock Options Exercised	$ 0	$ 66,000
ESPP [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | shares	950,000
Percentage of Voting Right not Eligible for ESPP	5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate	15%
Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date	85%
Share Based Compensation Arrangement By Share Based Payment Award, Maximum Amount of Shares Per Employee	$ 25,000,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | shares	9,381
Employee Benefits and Share-Based Compensation	$ 10,000
Four Grantees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	5 years
Modified Stock Options [Member]
Share-Based Payment Arrangement, Expense	$ 230,000
Modified Stock Options [Member] | One Grantee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)	24 months
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | shares	0
Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)	1 year
Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)	1 year
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of Installments	3

Note 9 - Stockholders Equity -

Note 9 - Stockholders Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Allocated share-based compensation expense	$ 586	$ 655
Cost of Sales [Member]
Allocated share-based compensation expense	1	0
Engineering and Product Development [Member]
Allocated share-based compensation expense	73	68
Selling and Marketing Expense [Member]
Allocated share-based compensation expense	131	199
General and Administrative Expense [Member]
Allocated share-based compensation expense	$ 381	$ 388

Note 9 - Stockholders Equity _2

Note 9 - Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Average risk-free interest rate	4.19%	1.46%
Expected dividend yield	0%	0%
Expected life (in years) (Year)	3 years	3 years 6 months
Granted, weighted average exercise price (in dollars per share)	$ 2.16	$ 5.22
Weighted average fair value (in dollars per share)	$ 1.14	$ 2.56
Minimum [Member]
Expected volatility	72.69%	66.30%
Maximum [Member]
Expected volatility	77.53%	69.50%

Note 9 - Stockholders Equity _3

Note 9 - Stockholders Equity - Summary of Stock Option Activity for Stock Option Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Outstanding, shares (in shares)	2,610,992
Outstanding, weighted average exercise price (in dollars per share)	$ 7.54
Outstanding, aggregate intrinsic value	$ 0		$ 0
Granted, shares (in shares)	541,142
Granted, weighted average exercise price (in dollars per share)	$ 2.16	$ 5.22
Granted, aggregate intrinsic value	$ 0
Exercised, shares (in shares)	0	(22,833)
Exercised, weighted average exercise price (in dollars per share)	$ 0
Exercised, aggregate intrinsic value	$ 0
Cancelled, shares (in shares)	(204,331)
Cancelled, weighted average exercise price (in dollars per share)	$ 9.27
Outstanding, shares (in shares)	2,947,803
Outstanding, weighted average exercise price (in dollars per share)	$ 9.44
Options Exercisable, shares (in shares)	1,985,026		1,619,855
Options Exercisable, weighted average exercise price (in dollars per share)	$ 7.44		$ 6.47
Options Exercisable, aggregate intrinsic value	$ 0		$ 0

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Expense (Benefit)	$ 5,000	$ 1,000
Effective Income Tax Rate Reconciliation, Percent	1%	1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%

Note 11 - Segment Reporting (De

Note 11 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2023
Number of Reportable Segments	2

Note 11 - Segment Reporting - S

Note 11 - Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total Revenue	$ 5,778	$ 7,523
Total gross profit	4,130	5,312
Interest expense	0	(9)
Interest income	150	0
Other income (expense), net	2	(13)
Loss before income tax	(3,773)	(3,544)
Operating Segments [Member]
Total Revenue	5,778	7,523
Total gross profit	4,130	5,312
Segment operating income (loss)	(1,007)	(587)
General, administrative, depreciation and amortization expense	(2,918)	(2,935)
Interest expense	0	(9)
Interest income	150	0
Other income (expense), net	2	(13)
Loss before income tax	(3,773)	(3,544)
Detection [Member] | Operating Segments [Member]
Total Revenue	4,334	5,521
Total gross profit	3,544	4,661
Segment operating income (loss)	(124)	622
Therapy [Member] | Operating Segments [Member]
Total Revenue	1,444	2,002
Total gross profit	586	651
Segment operating income (loss)	$ (883)	$ (1,209)

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) $ in Millions	Mar. 31, 2023 USD ($)
Purchase Obligation	$ 4.2
Royalty Obligations [Member]
Other Commitment	$ 0.2

Note 13 - Restructuring (Detail

Note 13 - Restructuring (Details Textual) - USD ($) $ in Thousands		3 Months Ended
	Mar. 20, 2023	Mar. 31, 2023
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	28%
Restructuring and Related Cost, Number of Positions Eliminated	23
Restructuring Costs		$ 76
Restructuring and Related Cost, Expected Cost Remaining		100
Employee Severance [Member]
Restructuring Costs		$ 80
Xoft Inc [Member]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	50%
Restructuring and Related Cost, Number of Positions Eliminated	12

Note 13 - Restructuring - Accru

Note 13 - Restructuring - Accrual for Restructuring Charges (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Charges	$ 76
Cash payments
Restructuring Costs	$ 76